The Human Papillomavirus vaccine: An oncology nursing issue

Catriona Buick, Kelly Metcalfe

Abstract


In Canada, approximately 1,500 women are diagnosed with cervical cancer every year, and 581 will die of the disease (WHO/ICO Information Centre on HPV and Cervical Cancer, 2007). The importance of preventing cervical cancer is clear, as the effects that this disease has on the lives of women and their families regardless of culture, sex, nationality or country is evident. With the recent media attention and release of the Human Papillomavirus (HPV) vaccine in Canada, it is crucial that oncology nurses understand HPV, its role in the development of cervical cancer, and the HPV vaccine. A brief overview of HPV and its involvement in the development of cervical cancer will be discussed in this paper. In addition, information on the HPV vaccine and its implications, as well as the current policy for the vaccine in Canada will be addressed. It will become evident how the role of the oncology nurse, as an educator and advocate regarding the implementation of this vaccine is crucial for successful acceptance of this vaccine. Finally, future implications of the vaccine and avenues of research will be touched upon.


Full Text:

PDF

References


American Cancer Society. (2006). HPV Vaccine Fights Cervical

Cancer. CA: A Journal For Clinicians, 56, 249–250.

Arbyn, M., & Dillner, J. (2007). Review of current knowledge on

HPV vaccination: An appendix to the European Guideline For

Quality Assurance in Cervical Cancer Screening. Journal Of

Clinical Virology, 38, 189–197.

Brotherton, J.M.L., Gold, M., Kemp, A.S., McIntyre, P.B., Burgess,

M.A., & Campbell-Lloyd, S. (2008). Anaphylaxis following

quadrivalent Human Papillomavirus vaccination. CMAJ, 179(6),

–533.

Burchell, A., Winer, R., de Sanjose, S., & Franco, E. (2006). Chapter

: Epidemiology and transmission dynamics of genital HPV

infection. Vaccine, S3/52–S3/61.

Cain, J., Denny, L., & Ngan, H.Y.S. (2007). Overcoming barriers to

eradication of cervical cancer: Women’s health and rights.

International Journal of Gynecology and Obstetrics, 97,

–234.

Canada Communicable Disease Report. (2007). National Advisory

Committee on Immunization: Statement on Human

Papillomavirus vaccine. Retrieved from

http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/07pdf/

acs33–02.pdf

Canadian Association of Nurses in Oncology. (2001). Standards

of Care for the Generalist, Specialized and Advanced

Oncology Nurse. Standard 3: Self Determination and

Decision-Making.

Canadian Cancer Society. (2007). Canadian Cancer Society

applauds funding for HPV vaccine announced in federal

budget. Retrieved June 12, 2007, from http://www.cancer.ca/

ccs/internet/mediareleaselist/0.3208.31721613121606180737433

langld-en.00.html

Cancer Care Ontario. (2002). 1997–2000 Ontario Cervical

Screening Program Report (270831). Toronto, ON:

Author.

Cancer Care Ontario. (2004). Human Papillomavirus (HPV) and

Cancer of the Cervix. Ontario Cervical Screening Program.

Cancer Care Ontario. (2007). Ontario announces HPV vaccination

program. Retrieved December 12, 2007, from

http://www.cancercare.on.ca/OntarioCancerNewsArchives/

/index_703.htm

Casey, D. (2007). Nurses’ perception, understanding and experiences

of health promotion. Journal of Clinical Nursing, 16,

–1049.

Comeau, P. (2007). Debate begins over public funding for HPV

vaccine. Canadian Medical Association Journal, 176(7),

–913.

Dunne, E., & Markowitz, L. (2006). Genital Human Papillomavirus

infection. Emerging Infections, 43, 624–629.

Franco, E., & Harper, D. (2005). Vaccination against Human

Papillomavirus infection: A new paradigm in cervical cancer

control. Vaccine, 23, 2388–2394.

FUTURE 11 Study Group. (2007). Quadrivalent vaccine against

Human Papillomavirus to prevent high-grade cervical lesions. The

New England Journal of Medicine, 356(19), 1915–19.

Garnett, G., & Waddell, H. (2000). Public health paradoxes and the

epidemiological impact of an HPV vaccine. Journal of Clinical

Virology, 19, 101–111.

GlaxoSmithKline. (2006). Cervarix®, GSK’s candidate vaccine for

cervical cancer demonstrated sustained efficacy for up to 4.5

years and broader protection against cancer-causing HPV

types. Retrieved March 18, 2008, from http://www.gsk.com/

ControllerServlet?appId=4&pageId=402&newsid=806

Goldie, S., Kohli, M., Grima, D., Weinstein, M., Wright, T., Bosch,

X., & Franco, E. (2004). Projected clinical benefits and costeffectiveness

of a Human Papillomavirus 16/18 vaccine. Journal

of The National Cancer Institute, 96(8), 604–615.

Government of Nova Scotia. (2007). HPV immunization

launched. Retrieved June 24, 2007, from:

http://www.gov.ns.ca/news/details.asp?id=20070620002

Gullatte, M. (2001). Prevention, screening and detection. In S.

Otto, Oncology Nursing (4th ed., pp. 53–77). St. Louis: Mosby

Inc.

International Collaboration of Epidemiological Studies of Cervical

Cancer. (2006). Cervical carcinoma and reproductive factors:

Collaborative reanalysis of individual data on 16,563 women with

cervical carcinoma and 33,542 women without cervical carcinoma

from 25 epidemiological studies. International Journal of

Cancer, 119, 1108–1124.

Kahn, J., & Bernstein, D. (2005). Human Papillomavirus vaccines

and adolescents. Current Opinion in Obstetrics and

Gynecology, 17, 476–482.

Kane, M. (2006). Developing HPV vaccine in the industrial and

developing world: The role of the Ob-Gyn community.

International Journal of Obstetrics and Gynecology, 94(Suppl.

, S89–S94.

Koutsky, L., & Harper, D. (2006). Current findings from prophylactic

HPV trials. Vaccine, S3, 114–121.

Lai, C., Huang, H., Hsueh, S., Chao, A., Lin, C., Huang, S., et al.

(2006). Human Papillomavirus genotype in cervical cancer: A

population-based study. International Journal of Cancer, 120,

–2006.

Merck & Co. (2008). Gardasil—The only cervical cancer vaccine.

Retrieved March 18, 2008, from: http://www.gardasil.com/

Moreira, E., Oliveira, B., Neves, R., Costa, S., Karic, G., & Filho, J.

(2006). Assessment of knowledge and attitudes of young

unisured women toward Human Papillomavirus vaccination and

clinical trials. Journal of Pediatric Adolescence Gynecology,

, 81–87.

Moscicki, A., Schiffman, M., Kjaer, S., & Villa, L. (2006). Chapter 5:

Updating the natural history of HPV and anogenital cancer.

Vaccine, S3/42–S3/51.

Munoz, N., Castellsague, X., Berrington de Gonzalez, A., &

Gissmann, L. (2006). Chapter 1: HPV in the etiology of human

cancer. Vaccine, S3/1–S3/10.

Newall, A., Beutals, P., Wood, J., Edmunds, W., & MacIntyre, C.

(2007). Cost-effectiveness analyses of Human Papillomavirus

vaccination. The Lancet, 7, 289–296.

Parkin, D., Bray, F., Ferlay, J., & Pisani, P. (2005). Global cancer

statistics, 2002. CA: A Cancer Journal For Clinicians, 55,

–108.

Perrin, K., Daley, E., Naoom, S., Packing-Ebuen, J., Rayko, H.,

McFarlane, M., & McDermott, R. (2006). Women’s reactions to

HPV diagnosis: Insights from in-depth interviews. Women And

Health, 43(2), 93–110.

Plummer, M., & Franceschi, S. (2002). Strategies for HPV

prevention. Virus Research, 89, 285–293.

Public Health Agency of Canada. (2007). Human Papillomavirus

(HPV) prevention and HPV vaccine: Questions and answers.

Retrieved June 12, 2007, from http://www.phac-aspc.gc.ca/

std-mts/hpv-vph/hpv-vph-vaccine_e.html

Ritvo, P., Wilson, K., Wilms, D., & Upshur, R. (2005). Vaccines in the

public eye. Nature Medicine Supplement, 11(4), S20–S24.

Saslow, D., Castle, P., Cox, T., Davey, D., Einstein, M., Ferris, D., et

al. (2007). American Cancer Society guidelines for Human

Papillomavirus vaccine use to prevent cervical cancer and its

precursors. CA: A Cancer Journal For Clinicians, 57, 7–28.

Sherman, M., Schiffman, M., Strickler, H., & Hildesheim, A. (1998).

Prospects for a prophylactic HPV vaccine: Rationale and future

implications for cervical cancer screening. Diagnostic

Cytopathology, 18(1), 5–9.

Sideri M., & Mariani, L. (2008). The HPV vaccine in Italy: How to

put research data into practice. Let the debate begin! HPV

Today. Retrieved November 5, 2008, from

http://www.g-o-c.org/uploads/hpvtoday_oct_2008.pdf

De Vuyst, H., Steyaert, S., Renterghem, L., Claeys, P., Muchiri, L.,

Sitati, S., et al. (2003). Distribution of Human Papillomavirus in a

family planning population in Nairobi, Kenya. Sexually

Transmitted Diseases, 30(2), 137–141.

Williamson, A., Passmore, J., & Rybicki, E. (2005). Strategies for the

prevention of cervical cancer by Human Papillomavirus vaccine.

Best Practice and Research Clinical Obstetrics and

Gynecology, 19(4), 531–544.

WHO/ICO Information Centre on HPV and Cervical Cancer.

(2007). Human Papillomavirus and cervical cancer.

Summary report on HPV and cervical cancer statistics in

Canada. Retrieved March 12, 2008, from

www.who.int/hpvcentre

Zimet, G. (2006). Understanding and overcoming barriers to Human

Papillomavirus vaccine and acceptance. Current Opinion in

Obstetrics and Gynecology, 18(Suppl. 1), S23–S28.

Zimmerman, R. (2007). HPV vaccine and its recommendations, 2007.

The Journal of Family Practice, 56(2), S2–S5.


Refbacks

  • There are currently no refbacks.


Bookmark and Share